OSOlga P. Sidorova

Olga P. Sidorova

*This is an algorithmically generated author record based on publicly available information.

Olga P. Sidorova has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Socialization of a patient with late-diagnosed classical phenylketonuria. Case report

    by Elena V. Proskurina, Olga P. Sidorova

    Classical phenylketonuria (PKU) is a group of autosomal recessive disorders characterized by hyperphenylalaninemia. Phenylketonuria is hyperphenylalaninemia caused by a deficiency of phenylalanine hydroxylase, leading to the accumulation of phenylalanine and its metabolic products in the body. Phenylketonuria is the most common inherited disorder with a known etiology and pathogenesis, and effective treatment. Phenylketonuria was the first disease for which screening was implemented, with newborn screening reaching 99%. Despite the fact that this screening has been performed for a long time, cases of late diagnosis are possible. This leads to significant cognitive impairment even despite treatment, which may necessitate the abandonment of dietary therapy in these patients. This article presents a case of a patient with a late diagnosis of classic PKU and a significant positive effect of dietary therapy, including the possibility of socialization. This demonstrates the necessity and potential of treatment even with a late diagnosis. The aim of this study is to demonstrate the effectiveness of dietary therapy for phenylketonuria, even with late diagnosis. A case of classic phenylketonuria diagnosed late (at age 3) in a 40-year-old female patient is described. Dietary therapy using special formulas has been beneficial, with successful socialization. She continues to adhere to the diet and uses the special formulas, although there have been interruptions. The patient completed school and music school, worked as a music teacher in a kindergarten, and as a registrar in a clinic. She writes popular music. Although there are a number of neurological abnormalities, including increased tendon reflexes, mild cognitive decline, difficulty planning actions and communicating with others, and infantility, the patient exhibits focal changes on an MRI of the brain. Nevertheless, this case presents the need for dietary intervention even in the case of late diagnosis of classical phenylketonuria, given that the patient is socialized, not only able to care for herself, but also has completed secondary education, worked in her field, and is engaged in creative activities.

  • Open Access

    Mitochondrial Complex IV Deficiency Nuclear Type 11 Caused by a Novel Start-Lost Variant in the COX20 Gene

    by Anna Kuchina, Artem Borovikov, Olga Sidorova, Maria Orlova, Oxana Ryzhkova, Igor Zaigrin, Aysylu Murtazina

    Background : The COX20 gene encodes a critical assembly factor for cytochrome C oxidase (complex IV), and biallelic loss-of-function variants in this gene cause mitochondrial complex IV deficiency, typically presenting in infancy or childhood with hypotonia, ataxia, neuropathy, or dystonia. Methods: This study describes an adult male patient with a broad clinical spectrum of central and peripheral nervous system involvement. Different medical genetic tests were performed for the patient, and only whole-genome trio sequencing identified pathogenic variants in the COX20 gene. A review of previously reported cases was conducted to compare clinical and imaging findings. Results: Two compound heterozygous COX20 variants in were identified: a known missense variant (c.41A>G; p.Lys14Arg) disrupting splicing, and a novel start-loss variant (c.2T>C; p.Met1?). The patient exhibited progressive ataxia, pyramidal signs, and peripheral neuropathy, accompanied by cervical spinal cord atrophy on spinal cord MRI and lower leg muscle fat infiltration on muscle MRI, an imaging feature not previously emphasized in COX20-related disease. Conclusions: A review of previously reported cases underscores broad clinical variability of the COX20-associated disorder, which may contribute to a prolonged diagnostic odyssey.

  • Criterion for the inactivity of multiple sclerosis (NEDA-3) after 3 years of extracorporeal photopheresis

    by Moscow Regional Research and Clinical Institute named after M.F. Vladimirskiy, O. P. Sidorova

    Extracorporeal photopheresis (extracorporeal photochemotherapy, extracorporeal photoimmunotherapy, or simply photopheresis) is a therapy based on exposure of peripheral blood leukocytes to ultraviolet radiation. A night incubation period is added to increase the efficiency of extracorporeal photopheresis. This modification of extracorporeal photopheresis is called «transimmunization». It induces the transformation of treated monocytes into cells expressing the phenotypic and functional features of dendritic antigen-presenting cells. Initially developed to treat cutaneous T-cell lymphoma, extracorporeal photopheresis has also proved effective in the treatment of graft-versus-host reactions, autoimmune diseases, and coronavirus infection, which is characterized by the development of autoimmune reactions. The purpose — to determine the effectiveness of transimmunization in patients with remitting multiple sclerosis using the NEDA-3 index for 3 years of treatment. Material and methods. 12 adult patients with remitting multiple sclerosis underwent transimmunization twice in a week every month for 6 months. Subsequently, the interval was increased each time by 1 month. Then the transimmunization was carried out twice a year. After 3 years from the start of treatment, the condition of patients was assessed using the criterion of «absence» of signs of disease activity (NEDA-3). The EDSS scale and MRI of the brain were used. Results. During the entire three-year treatment period, NEDA-3 was registered in 5 out of 12 patients (41,67%). Conclusion. Transimmunization (modification of extracorporeal photopheresis) had a positive effect on the condition of patients with remitting course of multiple sclerosis. The method can be used along with other methods of treating the disease to prevent disability of patients and improve their quality of life.

  • Open Access

    Intellectual development disorder syndrome with congenital anomalies of type 99, faceted female (OMIM: 300968), updated mutation in the USP9X gene

    by A. Sh. Latypov, Е. В. Проскурина, O. P. Sidorova, I. A. Vasilenko, D. V. Kassina, M. S. Bunak

    The syndrome of mental retardation with congenital anomalies of type 99, limited to the female sex (OMIM: 300968) is an X-linked dominant disorder of the development of the central nervous system, characterized by delayed psychomotor development and mild or moderate mental retardation.In the article, a clinical case of a 2-year-old 8-month-old patient with mental retardation syndrome and type 99 congenital anomalies characteristic only of the female sex (OMIM: 300968) is presented. Due to the heterozygous carriage of a previously undescribed pathogenic variant with a reading frame shift in the X-linked USP9X gene associated with a type 99 developmental disorder with dominant inheritance, in chrX:41196714AATTGA, ENST00000378308, C.4214_4217delATT.P.Asp1405fs. The pathogenic variant was confirmed in the child in the study of the trio by Sanger. It is absent from the parents (a new pathogenic variant). Along with cognitive impairments, the patient revealed congenital anomalies, some of which coincided with those previously described. There were also some special features: the asymmetry of the skull in the described patient was expressed in the parietal part of the skull, and not the facial one, as described in previous publications. Secondary mitochondrial disorders were revealed during the study of the activity of mitochondrial enzymes in peripheral blood lymphocytes, which are an “enzymatic mirror” of tissues, which is an indication for the appointment of energotropic drugs (succinic acid and carnitine).

  • Open Access

    Mitochondrial disorders in patients with familial form of MERRF syndrome

    by A. Sh. Latypov, E. V. Proskurina, S. V. Kotov, O. P. Sidorova, I. A. Vasilenko, D. V. Kassina, A. S. Kotov

    MERRF syndrome (myoclonic epilepsy ragged red fibres) belongs to the group of primary mitochondrial diseases and is characterized by a combination of myoclonic epilepsy and the phenomenon of ragged red fibres on muscle biopsy. The aim of this work is to study mitochondrial disorders in patients from a family with MERRF syndrome by determining the cytochemical activity of mitochondrial enzymes in peripheral blood lymphocytes and the level of lactate in the blood. Clinical cases of a 25-year-old sister and a 19-year-old brother with MERRF syndrome with the m.8344AG variant in MT-TK (tRNA (Lys)) with a blood heteroplasmy level of 50 % in the sister and homoplasmy in the brother are presented. Mitochondrial disorders were assessed by blood lactate levels and cytochemical studies of mitochondrial enzyme activity in peripheral blood lymphocytes. Pre-prandial blood lactate levels were elevated in both patients. After a carbohydrate load, it increased in the sister, and decreased in the brother. The sister had decreased activity of peripheral blood lymphocyte enzymes while taking levetiracetam, 100 mg of coenzyme Q10 and 100 mg of L-carnitine. The dose of energotropic drugs was increased, which led to an increase in the activity of mitochondrial enzymes. The brother had a compensatory increase in the level of succinate dehydrogenase and a decrease in the activity of other enzymes. The methods we used can be used in clinical practice to diagnose mitochondrial disorders and to adjust the dosage of energotropic drugs, which remain relevant due to the lack of effective gene therapy.

  • Open Access

    Physiological Improvement in Patients with Charcot-Marie-Tooth Disease by Pharmacological Doses of Thiamine Correlates with Increased Blood Levels of Thiamine Diphosphate

    by Artem V. Artiukhov, Olga N. Solovjeva, Natalia V Balashova, Olga P Sidorova, Aastasia V Graf, Victoria I Bunik

    Charcot-Marie-Tooth (CMT) neuropathy is a polygenic disorder of peripheral nerves with no effective cure. Thiamine (vitamin B1) is a neurotropic compound improving neuropathies. Our study shows therapeutic potential of daily oral administration of thiamine or its membrane-penetrating form sulbutiamine in CMT patients, by following their physiological performance along with the blood levels of the thiamine coenzyme form (thiamine diphosphate, ThDP), endogenous transketolase (TK) activity (holoTK), total TK activity (holoTK and apoTK) and TK saturation with ThDP (holoTK/(holoTK+apoTK)). The CMT patients exhibit significant positive correlation of the blood ThDP with the hand grip strength. Both thiamine and sulbutiamine may decrease a minor fraction of TK apoenzyme, shifting the TK activities to their lower limit of 0.03-0.04 U/mL. Although the average levels of ThDP, holoTK or apoTK do not significantly differ between CMT and control groups, high interpersonal variations in the levels of ThDP and activation of TK by ThDP are inherent in the control, but not CMT, subjects. The difference is associated with a statistically significant TK activation and positive correlation of the levels of ThDP and endogenous holoTK in the control subjects only. Gender dependence of negative correlations between the blood levels of apoTK and ThDP, and the dependence reversal in CMT patients vs. controls are shown. Thus, physiological benefits of pharmacological doses of thiamine in CMT patients are linked to changes in the thiamine-dependent metabolic network in the disease vs. healthy state.

  • Open Access

    Hyperhomocysteinemia as a risk factor for cerebral vascular thrombosis in a child with a traumatic brain injury. Clinical observation

    by С. В. Котов, О. П. Сидорова, А. С. Котов, Е. В. Проскурина, О. А. Соловова

    Приводятся клиническое наблюдение пациента с гипергомоцистеинемией и краткий обзор литературы, посвященный данной проблеме (диагностика и лечение). Тромбоз сосудов головного мозга – одна из наиболее частых причин летального исхода. Выявление этиологии заболевания является актуальным для тактики лечения и профилактики тромбозов. Причинами тромбозов сосудов головного мозга, в том числе у детей, могут быть гипергомоцистеинемия, мутации в генах тромбофилии. Описывается клиническое наблюдение ребенка 15 лет с тромбозом глубоких вен мозга, венозных синусов. Проведены тандемная масс-спектрометрия и таргетное секвенирование. Определено двукратное повышение уровня гомоцистеина и метионина в сыворотке крови. При секвенировании гена CBS (ген цистатионин бета-синтазы) выявлена мутация, описанная в международной базе данных HGMD(СM970234) NM_000071:c.785 C>T (p.T262M) в гетерозиготном состоянии. Также выявлена ранее не описанная замена в гене CBS NM_000071:c. 352 G>A (p.V118M), программами оценки патогенности генетических вариантов расцененная как высоковероятно патогенная. The clinical observation of the patient and a brief review of the literature on this problem (diagnosis and treatment) are given. Cerebral vascular thrombosis is one of the most common causes of death. The identification of the etiology of the disease is relevant for the tactics of treatment and prevention of thrombosis. The causes of cerebral vascular thrombosis, including in children, may be hyperhomocysteinemia, mutations in the genes of thrombophilia. The clinical observation of a 15-year-old child with deep vein thrombosis of the brain, venous sinuses is described. Tandem mass spectrometry and targeted sequencing were performed. A twofold increase in the level of homocysteine and methionine in the blood serum was determined. When sequencing the CBS gene (cystathionine beta-synthase gene) a mutation described in the international mutation database HGMD(CM970234) NM_000071 has been identified:c.785 C>T (p.T262M) in a heterozygous state. A replacement in the CBS gene NM_000071:c. 352 G>A (p.V118M), undescribed in the international database for HGMD mutations and dbSNP polymorphism, was also identified, but according to pathogenicity programs it is highly likely pathogenic. Conclusion: cerebral vascular thrombosis in children is a rare condition, so it is important to search for the genetic cause of the disease.

  • Familial Case of Porphyria with an Epileptic Seizure in the Moscow Region

    by A. Latypov, S. Kotov, E. Proskurina, O. Sidorova, A. Kotov

    Objective a clinical case of a 37-year-old patient with familial acute porphyria is presented (the patient's sister died at the age of 28 during an attack of acute porphyria). Material and methods: we used a qualitative urine test for porphyria with Erdich reagent and quantitative determination of porphyrins (porphobilinogen and delta-aminolevulenic acid on a spectrophotometer “Hitachi 3900”. Results.The attack began with pain in the abdomen and lower back, tachycardia, arterial hypertension during menstruation. After taking ketorol and surgical intervention, tonic-clonic convulsions developed with involuntary release of pink urine. CT of the brain shows signs of ischemic cerebrovascular accident in the parietal region of the right hemisphere. There was a decrease in the level of hemoglobin in the blood and APTT. A urine test for porphyria was positive. Porphobilinogen and delta-aminolevulinic acid in the blood are elevated. After the appointment of glucose at a dose of 300 g of dry matter per day in an oral solution, the condition improved. Conclusion. The presented case demonstrates the difficulties in diagnosing and managing patients with acute porphyria, despite the awareness of the attending physicians about this disease. The patient developed an epileptic seizure and brain damage according to CT, which could be posterior reversible encephalopathy. To improve the efficiency of diagnosis and treatment of porphyria in all laboratories, a simple and cheap qualitative urine test for porphyria with Ehrlich's reagent should be organized and Hitachi 3900 spectrophotometers should be purchased at regional medical centers. Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

  • Mitochondrial Disorders and MRI of the Brain in Patients with Leukoencephalophathy with Brainstem and Spinal Cord Involvement and Lactate Elevation in Moscow Region

    by S. Kotov, O. Sidorova, I. Vasilenko, M. Bunak, A. Borodin, D. Kassina

    Leukoencephalopathy with lesions of the brainstem and spinal cord and increased lactate levels (LBSL) is a hereditary autosomal recessive disease caused by a mutation in the DARS2 gene, with a heterogeneous lesion of the white matter of the brain involving the brainstem and spinal pathways, an increase in lactate in abnormal white matter. Objective. The purpose of the study is to evaluate the features of brain MRI and mitochondrial disorders in adult patients with PE-FMF. Material and methods. An observation of three adult patients from the Moscow region with a hereditary mitochondrial disease of leukoencephalopathy with damage to the brainstem and spinal cord and an increase in lactate level (LBSL) is presented. The diagnosis was confirmed by molecular diagnostics. An MRI examination of the brain was performed on an MRI tomograph with a magnetic field induction of 3.0 T For the cytochemical study of the activity of mitochondrial enzymes in peripheral blood lymphocytes, the method proposed by A.G.E. Pearse modified by R.P. Narcissov. Results. The clinical picture of the disease is similar to multiple sclerosis. MRI of the brain showed more pronounced diffuse changes in the white matter. In all patients, dysfunction of the respiratory chain of mitochondria was noted. Conclusion. Taking into account the data obtained, patients are shown energotropic therapy (idebenone and carnitine preparations). Thus, when doubtful cases in the diagnosis of multiple sclerosis, LBSL should be excluded.

  • Open Access

    Torsion dystonia type 30. Clinical observation. Case report

    by Artur Sh. Latypov, Sergey V. Kotov, Elena V. Proskurina, Olga P. Sidorova, Ekaterina S. Novikova, Irina A. Vasilenko, Darya V. Cassina, Кассина Дарья Валерьевна

    A 58-year-old patient with type 30 dystonia (OMIM619291) detected by genome-wide sequencing was described. A variant of rs778751388, not previously described in the literature, has been identified in the heterozygous state in exon 2 of 24 of the VPS16 gene, leading to the amino acid substitution of P.Cys36A4rg. DNA change (HG38)(protein change) 20:g.2859771TC ENST00000380445.8:c.106TC ENSP00000369810.3:p.Cys36Arg. The patient's disease began quite late, in the 4th decade of life, with spastic torticollis. Subsequently, the spread of the pathological process involving the muscles of the neck, the right upper limb, then the right lower limb, myoclonia of the right hand and tremor of the right lower limb was noted. Secondary mitochondrial disorders were revealed in the form of an increase in the level of lactate in the blood before and after loading with carbohydrates. A decrease in the activity of mitochondrial enzymes in peripheral blood lymphocytes was also revealed: succinate dehydrogenase, an enzyme of the mitochondrial respiratory chain complex II; -glycerophosphate dehydrogenase involved in mitochondrial fat metabolism; glutamate dehydrogenase (amino acid metabolism in mitochondria). The level of lactate dehydrogenase in peripheral blood lymphocytes in the patient was elevated. The identified secondary mitochondrial disorders may be an indication for the appointment of energotropic medicines along with levodopa drugs and dopaminergic receptor agonists. In the presented observation, it can be argued about autosomal dominant inheritance, since the patient has a characteristic clinical picture of the disease and a mutation in the heterozygous state in the VPS16 gene was detected.